Valuation: TAUNS Laboratories,Inc.

Market Cap 49.99B 309M 271M 250M 231M 438M 29.52B 445M 2.98B 1.17B 14.54B 1.16B 1.14B P/E 2025
8.67x
P/E 2026 * 9.43x
Enterprise Value 56.82B 352M 308M 284M 262M 497M 33.55B 506M 3.39B 1.33B 16.53B 1.32B 1.29B EV / Sales 2025
3.23x
EV / Sales 2026 * 3.93x
Free-Float
29.82%
Yield 2025
5.2%
Yield 2026 * 7.52%
1 day+0.86%
1 week+0.86%
Current month-0.64%
1 month-3.89%
3 months-6.94%
6 months-10.33%
Current year-7.86%
1 week 464
Extreme 464
474
1 month 463
Extreme 463
492
Current year 463
Extreme 463
568
1 year 463
Extreme 463
603
3 years 401
Extreme 401
733
5 years 401
Extreme 401
733
10 years 401
Extreme 401
733
Manager TitleAgeSince
Chief Executive Officer 51 01/05/2014
Director of Finance/CFO 66 01/11/2018
Corporate Officer/Principal 39 01/07/2022
Director TitleAgeSince
Director/Board Member 62 01/09/2020
Director/Board Member 53 01/04/2016
Director/Board Member 39 01/09/2024
Change 5-day change 1-year change 3-year change Capi.($)
+0.86%+0.86%-11.68% - 309M
-2.46%-4.72%+212.05%+318.32% 21.22B
-2.58%+0.14%-42.60%-22.89% 9.41B
-0.33%-3.87%+26.02%+24.49% 6.88B
-0.86%+9.54%+238.59%-26.38% 5.42B
-4.92%-7.16%-36.18% - 4.8B
+3.74%-1.63%-21.48%-28.55% 5.05B
-1.04%-1.40%-24.44%-24.84% 4.17B
+0.75%-11.50%+60.79%+69.60% 3.64B
+0.62%-0.77%-18.44%-39.92% 2.59B
Average -0.62%-0.82%+38.26%+33.73% 6.35B
Weighted average by Cap. -1.38%-1.70%+84.38%+110.76%

Financials

2025 2026 *
Net sales 19.06B 118M 103M 95.21M 87.93M 167M 11.25B 170M 1.14B 447M 5.54B 443M 433M 14.76B 91.36M 79.91M 73.71M 68.07M 129M 8.71B 131M 881M 346M 4.29B 343M 336M
Net income 6.5B 40.24M 35.2M 32.47M 29.98M 56.9M 3.84B 57.85M 388M 152M 1.89B 151M 148M 5.2B 32.2M 28.17M 25.98M 24M 45.53M 3.07B 46.3M 310M 122M 1.51B 121M 118M
Net Debt 6.83B 42.28M 36.98M 34.11M 31.51M 59.78M 4.03B 60.79M 408M 160M 1.99B 159M 155M 7.99B 49.49M 43.29M 39.93M 36.88M 69.98M 4.72B 71.15M 477M 187M 2.33B 186M 182M
Logo TAUNS Laboratories,Inc.
Tauns Laboratories Inc is a Japan-based company engaged in the business of developing, manufacturing and marketing in vitro diagnostic products and research reagents. The Company operates its business in the in vitro diagnostic products business segment. The Company’s main product is antigen test kit that uses immunochromatography to enable rapid diagnosis at the patient's side without the need for special equipment. The products include ImunoAce Flu, ImunoAce SARSCoV-2 II, ImunoAce SARSCoV-2 Saliva, ImunoAce SARSCoV-2/Flu, ImunoAce Adeno, ImunoAce Strep A Neo, ImunoAce hMPV, ImunoAce Mycopiasma, ImunoAce RSV Neo and ImunoAce Noro.
Employees
218
Date Price Change Volume
10/07/26 JP¥469.00 +0.86% 314,400
09/07/26 JP¥465.00 -0.43% 237,200
08/07/26 JP¥467.00 -0.64% 200,200
07/07/26 JP¥470.00 +0.64% 147,300
06/07/26 JP¥467.00 +0.43% 448,100
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
2
Last Close Price
469.00JPY
Average target price
420.00JPY
Spread / Average Target
-10.45%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 197A Stock